Clinical experience with ximelagatran in orthopaedic surgery

Drugs

Volumn 64, Issue SUPPL. 1, 2004, Pages 27-35

  Eriksson, Bengt ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; WARFARIN; XIMELAGATRAN;

BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; MONITORING; REVIEW; THROMBOCYTOPENIA; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM; CLINICAL EVALUATION; CLINICAL PRACTICE; ELECTIVE SURGERY; EMBOLISM PREVENTION; EXPERIENCE; MAJOR SURGERY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); ORTHOPEDIC SURGERY; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOSIS PREVENTION; UNITED STATES;

EID: 4644285241     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464001-00005     Document Type: Review

References (20)

1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119 (1 Suppl.): 132S-75S
2. Paiement GD, Desautels C. Deep vein thrombosis: prophylaxis, diagnosis, and treatment - lessons from orthopaedic studies. Clin Cardiol 1990; 13 (4 Suppl 6.): VI19-22
3. Deitelzweig SB, Vanscoy GJ, Niccolai CS, et al. Venous thromboembolism prevention with LMWHs in medical and orthopaedic surgery patients. Ann Pharmacother 2003; 37 (Pt 3): 402-11
4. Fabris F, Luzzatto G, Stefani PM, et al. Heparin-induced thrombocytopenia. Haematologica 2000; 85 (Pt 1): 72-81
5. Eriksson UG, Bredberg U, Gislen K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003; 59 (Pt 1): 35-43
6. Eriksson UG, Mandema JW, Karlsson MO, et al. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Clin Pharmacokinet 2003; 42 (Pt 7): 687-701
7. Eriksson BI, Arfwidsson AC, Frison L, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost. 2002; 87 (Pt 2): 231-7
8. Eriksson BI, Bergqvist D, Kalebo P, et al. Melagatran for thrombin inhibition in orthopaedic surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360 (9344): 1441-7
9. Eriksson BI, Agnelli G, Cohen AT, et al. METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003; 89 (Pt 2): 288-96
10. Dahl O, Eriksson BI, Agnelli G, et al. Influence of time of first dose on the efficacy and safety of postoperative ximelagatran for prevention of thromboembolism after orthopaedic surgery. Pathophysiol Haemost Thromb 2003; 33 (Suppl. 2): 38 [abstract OC068]. Presented at 18th International Congress on Thrombosis, 20-24 June 2004, Ljubljana, Slovenia
11. Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490-6
12. Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systemic review. Arch Intern Med 2001; 161: 1952-60
13. Cohen AT, Agnelli G, Dahl OE, et al. Efficacy and safety of the treatment regimen of melagatran and ximelagatran for prevention of thromboembolic events after total hip or knee replacement: a meta-analysis of 3 randomized, double-blind studies, to evaluate the influence of time and dose [poster]. XIXth Congress of the International Society on Thrombosis and Haemostatsis (ISTH); 2003 July 12-18; Birmingham, UK
14. Francis CW, Berkowitz SD, Comp PC, et al. EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349 (Pt 18): 1703-12
15. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002; 137 (Pt 8): 648-55
16. Colwell CW Jr, Berkowitz SD, Comp PC, et al. Randomized double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B [abstract no. 39]. Blood 2003; 102 (Pt 11): 14A, Abs 39
17. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. Arch Intern Med 2001; 161 (Pt 18): 2215-21
18. Colwell CW Jr, Berkowitz D, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003; 1 (Pt 10): 2119-30
19. Schulman S, Wahlander K, Lundstrom T, et al. THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349 (Pt 18): 1713-21
20. Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362 (9397): 1691-8